Brivanib Versus Sorafenib As First-Line Therapy in Patients...

Journal of Clinical Oncology 2013 / 10 Vol. 31; Iss. 28

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., Lu, L., Chao, Y., Boucher, E., Han, K.-H., Paik, S.-W., Robles-Avina, J., Kud
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/jco.2012.48.4410
Date:
October, 2013
File:
PDF, 236 KB
english, 2013
Conversion to is in progress
Conversion to is failed